FAIR VALUE MEASUREMENTS - Narrative (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | 12 Months Ended | ||||
|---|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Dec. 31, 2025 |
Dec. 31, 2024 |
Aug. 30, 2024 |
|
| Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||||||
| Increase in fair value of strategic investments | $ 800 | $ 2,200 | $ 1,700 | $ 3,000 | |||
| Fair value of strategic investment | 65,300 | $ 63,700 | $ 55,000 | ||||
| Increase in fair value of strategic equity investments | 0 | 600 | |||||
| Contingent consideration | 21,002 | 21,002 | 20,407 | ||||
| Level 3 | |||||||
| Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||||||
| Contingent consideration | $ 21,002 | $ 21,002 | $ 20,407 | ||||
| BioIntelliSense, Inc. | |||||||
| Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||||||
| Contingent consideration | $ 17,000 | ||||||